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Introdution 
Metamorphopsia is a type of optic illusion in which the size, shape, or angulation of objects is perceived as 
altered. Individuals typically see lines as wavy or curly instead of straight and flat surfaces as curved [1]. It is 
a rare manifestation of an acute central nervous system insult, mainly to the visual or vestibular systems [1]. 
It is a symptom caused by disorders of the retina or choroid and frequently observed in age-related macular 
degeneration; it may occur, although less frequently, as the result of retinal detachments because of direct 
eye injuries or head trauma [2].  
Metamorphopsia may also occur although rarely as an adverse drug reaction (ADRs); an analysis of case 
reports from the National Registry of Drug-Induced Ocular Side Effects of the United States of America 
reports has identified bisphosphonates, cetirizine, retinoids and topiramate as the drugs mostly involved in  
ocular ADRs [3].  
To date, the ocular ADRs are not included in the side effects reported in the Summary of Product 
Characteristics (SPC or SmPC) of montelukast, a potent leukotriene-receptor antagonist, and the possible 
correlation between its use and the ocular event has not yet been investigated. Montelukast is administered 
once daily in the treatment of asthma and allergic rhinitis in children and adults [4]. Efficacy and safety 
profile data on montelukast from several paediatric studies have been published. While generally well 
tolerated, it may lead to clinical adverse reactions such as upper respiratory infection, worsening asthma, 
pharyngitis and headache [5-7]. 
In this study, we present the first case in which montelukast can be linked to the onset of metamorphopsia 
[8]. We then propose a possible mechanism leading to its insurgence and provide an analysis of international 
pharmacovigilance database to map its occurrence.  
Detail of the case 
A 12-years-old female suffering from asthma was treated with montelukast at the therapeutic dose (5 
mg/day). Approximately an hour after the first oral administration of the drug, the patient experienced visual 
disturbance in which the perfectly straight lines appeared wavy, parts of the line appeared blank with flat 
surface bending. This visual disturbance  lasted approximately 15 minutes. The patient was hospitalised. The 
neurological examination and the electroencephalogram revealed no abnormalities. The positive Amsler test 
confirmed the diagnosis of metamorphopsia. The patient received no other concomitant drug or herbal 
treatment and had no personal or family history of ocular diseases. 
Considering the temporality between the drug intake and the appearance of the reaction, the treatment was 
discontinued and a diagnosis of iatrogenic metamorphopsia was performed by the clinician. The ADR 
resolved after drug withdrawal in few days. The patient no longer experienced ocular disturbances and 
remained metamorphopsia-free during a 3-month follow-up. 
The positive dechallenge, the temporal association between drug’s use and the onset of the reaction 
suggested a possible causal relationship between the metamorphopsia and montelukast administration, 
confirmed also by the Naranjo Algorithm.  
Analysis of Pharmacovigilance databases 
Montelukast-associated metamorphopsia has not previously been reported in the literature [8], although the 
main International pharmacovigilance databases contain several reports of ocular event referred to the 
leukotriene-receptor antagonist.  
We retrieved 719 reports of ocular ADRs in which montelukast was the suspected drug involved, inserted 
into the following pharmacovigilance databases: the Danish Health and Medicines Authority, the Health 
Canada Vigilance Adverse Reaction Online Database, the Netherlands Pharmacovigilance Centre Lareb 
Databank, the UK Medicines and Healthcare products Regulatory Agency, the FDA Adverse Event 
Reporting System (AERS), the Australian Adverse Event Reporting System (DAEN) (Table 1). Of 719 
ocular ADR reports 4 of those in the AERS described metamorphopsia, representing the 0.5% of the total 
ocular events retrieved in our analysis. Of these, one refers of a 13-year-old male with multiple allergies who 
was placed on therapy with montelukast (strength, formulation and indication not reported). Approximately 5 
minutes after montelukast administration, the patient experienced visual disturbance with metamorphopsia. 
The limit of this analysis is that the pharmacovigilance databases only receives reports of the most critical 
and severe cases; these numbers we retrieved may underestimate the complication rate of the drug. 
Discussion 
The adverse ocular drug-related events are scant in general and rare with montelukast. Previous studies have 
estimated that ocular disorders such as myopia and conjunctivitis can occur in patients taking montelukast 
with an incidence of 2%; mydriasis is among the most frequent adverse effects with overdosage of the drug 
[8, 12].  
The pathogenic causes of montelukast associated metamorphopsia may be multiple and not necessarily 
mutually exclusive. Metamorphopsia, is often the result of progressive accumulation of fluid in the rear area 
of the ocular fundus, can lead to the perception of a visual field deformed [3]. It is therefore plausible that 
inflammation and peripheral oedema play an important role in this visual disturbance [18]. Inflammatory 
processes and the increase in vascular permeability are indeed responsible of macular oedema resulting in 
metamorphopsia. The release of inflammatory mediators such as histamine and products of arachidonic acid 
metabolism has been demonstrated in bronchoalveolar fluid of patients with asthma [19], and in some cases 
montelukast is able to cause peripheral oedema [17]. In the specific case we observed a partial inefficacy of 
montelukast in reducing pro-inflammatory mediators combined with a possible direct oedemigen effect of 
the drug may have synergised to trigger metamorphopsia [20].  
A second possibility is headache, often associated with bizarre visual and spatial distortions [21]. Headache 
has been commonly reported (>1/100 to <1/10) in clinical studies enrolled asthmatic patients treated with 
montelukast. In our analysis, the ocular ADRs reports have frequently involvement of headache and 
migraine probably resulting in the predisposition of visual disturbance. 
Finally, metamorphopsia can be also caused by psychiatric disorders [22], also detected in patients with 
asthma, who are at increased risk for a variety of mental disorders [23]. Montelukast can cause psychiatric 
adverse reactions; they are rare but involve mostly hallucinations including visual hallucinations [24,25]. It 
has been suggested that inhibition of leukotriene receptors in the brain could be responsible for these 
neuropsychiatric adverse effects [23]. Interestingly in one case montelukast was associated with the Alice-in-
Wonderland syndrome that associate disorienting neurological conditions with metamorphopsia [9]. Also in 
this case no obvious trigger and negative magnetic resonance imaging and electroencephalography were 
reported [9-11].  
Our current case report, along with previous data form literature and the International pharmacovigilance 
databases, identify in metamorphopsia a possible ADR by montelukast and provide a rationale for its 
occurrence. These results provide also means to help the physician to identify possible correlations between 
ocular side effects and montelukast for a prompt identification. An increased attention in pharmacovigilance 
to this ADR appears relevant because of the wide paediatric use of montelukast. 
Table 1. Ocular ADRs in which montelukast was involved as suspected drug, inserted into the International 
pharmacovigilance databases. 
 
Pharmacovigilance 
databases 
N° of 
ADR 
reports  
belong to 
SOC Eye 
Disorder 
N° of 
reports of 
metamorpho
psia 
ADR belong to SOC Eye 
Disorder mostly reported 
Period of 
observation 
(from-to) 
Danish Health and 
Medicines Authority 
 
11 - 
xerophtalmia, blepharospasm, 
eye swelling, periorbital 
oedema*, eye pruritus, 
pupillary disorder, retinal 
deposits, visual impairment 
1998-2015 
Health Canada Vigilance 
Adverse Reaction Online 
Database 
18 - visual impairment, blindness 
transient, hyperhidrosis, 
periorbital oedema, 
blepharospasm, cough*, drug 
ineffective*, pyrexia*, 
somnolence*, dry eye, 
excessive eye blinking, eye 
movement disorder 
1998-2015 
Netherlands 
Pharmacovigilance 
11 - conjunctival haemorrhage, dry 
eye, visual impairment, 
1998-2015 
Centre Lareb Databank lacrimal disorder, vision 
blurred 
UK Medicines and 
Healthcare products 
Regulatory Agency 
 
62 - Cataract, eye disorder 
periorbital oedema, eye pain, 
eye movement disorder, 
mydriasis, photopsia vision 
blurred, visual impairment 
1998-2015 
AERS 
 
611 4 
photopsia, eye disorder, dry 
eye, periorbital oedema, 
dizzness*, visual impairment, 
headache*, nausea*, anxiety*, 
vision blurred, visual 
disturbance, vision blurred, 
cataract, paraesthesia, visual 
field defect, eye pain 
2004-2012 
DAEN 
 
6 - headache*, migraine*, 
nausea*, visual impairment, 
periorbital oedema, dizziness*, 
fatigue*, vomiting*, photopsia, 
visual field defect, peripheral 
oedema *   
1998-2015 
TOTAL 719 
4 
 
 
- not reported 
* ADRs reported in association to ADRs detected using for the screening the SOC Eye Disorder  
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